Please login to the form below

Not currently logged in
Email:
Password:

MEDI4736

This page shows the latest MEDI4736 news and features for those working in and with pharma, biotech and healthcare.

AZ gets orphan status for selumetinib in thyroid cancer

AZ gets orphan status for selumetinib in thyroid cancer

immuno-oncology candidate durvalumab (MEDI4736).

Latest news

More from news
Approximately 6 fully matching, plus 28 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    AstraZeneca will collaborate with Peregrine on a non-exclusive basis looking at the combination of bavituximab and durvalumab [MEDI4736] in solid tumours.

  • Pharma deals in April 2015 Pharma deals in April 2015

    Completing the deal haul is the exclusive collaboration around AZ's MEDI4736 for an upfront payment of $450m plus royalties. ... MEDI4736 is an immune checkpoint inhibitor which is targeted against programmed cell death (PD-L1).

  • Medius Deal Watch table for April 2015 Medius Deal Watch table for April 2015

    485. AstraZeneca/Celgene. Exclusive collaboration. MEDI4736 - an investigational checkpoint inhibitor in serious blood cancers.

  • Pharma deals during November 2014 Pharma deals during November 2014

    AZ has been busy this month and in the deal with J&J, AZ will match its closely-watched PD-L1 checkpoint inhibitor MEDI4736 with Imbruvica. ... MEDI4736 blocks the signals that help tumours avoid detection by the immune system, countering the tumour's

  • Pharma deals during July 2014 Pharma deals during July 2014

    The focus of the study will be KHK's anti-CCR4 antibody, mogamulizumab, in combination with either AZ's anti-PD-L1 antibody, MEDI4736, or AZ's anti-CTLA-4 antibody

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics